Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
20 participants
OBSERVATIONAL
2021-03-01
2022-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The samples will be processed after their extraction. The concentration of the samples will be analyzed using a high-performance gilent infinity liquid chromatograph coupled to a mass spectrometer using positive or negative ionization using electrospray.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cases
Patients treated with ceftriaxone doses equal to or higher 4 grams / day.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Creatinine \<1.5 mg / dL
* The patient must have received at least 48 hours of treatment with the same previous therapeutic regimen to extraction.
* The subject or her representative must give their verbal or written consent to participate in the study. East Consent can be revoked at any time without prejudice to the patient.
The consent it will be recorded in your medical record.
Exclusion Criteria
* Creatinine\> 1.5 mg / dL
* Patient with less than 48 hours of treatment with high-dose ceftriaxone.
* Subjects with allergy or hypersensitivity to cephalosporins and penicillins.
* Subjects who do not grant or withdraw their consent.
* Patients whose concomitant treatment presents possible interactions with the study medication. The possible interactions will be evaluated by staff of the Pharmacy Service.
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Maria Victoria Gil Navarro
Role: PRINCIPAL_INVESTIGATOR
Hospitales Universitarios Virgen del Rocío
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Universitario Virgen del Rocío
Seville, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Maria Victoria Gil Navarro
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FIS-CEF-2021-01
Identifier Type: -
Identifier Source: org_study_id